secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2022-06-27T23:59:59+00:00
Accession:  0001193125-22-182828
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA rejects Spero's tebipenem HBr NDA for cUTI; additional clinical study required
--------------------------------------------------------------------------------

- Received Complete Response Letter on June 27, 2022 for tebipenem HBr oral tablets cUTI NDA.
- FDA determined Phase 3 ADAPT-PO study insufficient; additional clinical study needed.
- Company plans to request a Type A meeting with FDA to discuss path forward.
- CEO expressed disappointment but commitment to pursue regulatory approval and potential partnerships.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312522182828/0001193125-22-182828-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312522182828/d373789d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-182828

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer